Study: NCT03330405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Phase 1b
Description: Avelumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Phase 1b
Description: Avelumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Phase 1b
Description: Avelumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Phase 1b
Description: Talazoparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Phase 1b
Description: Talazoparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Phase 1b
Description: Talazoparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Phase 2
Description: The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.